Navigation Links
Cancer drug slows poxvirus in mice

Mice given a relatively new cancer drug can survive an otherwise lethal dose of vaccinia virus, a relative of smallpox virus, report scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The findings, say the investigators, suggest that Gleevec or similar drugs might be useful in preventing adverse side effects of smallpox vaccine. The classic smallpox vaccine is made from live, weakened vaccinia virus and is not recommended for people with compromised immunity, except in emergency situations where they may have been exposed to smallpox virus.

"This study helps illuminate the cellular machinery used by poxviruses to exit infected cells, and also provides new support for the concept of treating viral infections by targeting specific host cell molecules rather than the viruses themselves," says NIAID Director Anthony S. Fauci, M.D.

The senior author of the paper, published online this week in the journal Nature Medicine, is Daniel Kalman, Ph.D., of Emory University School of Medicine in Atlanta.

Like all viruses, poxviruses co-opt various cellular molecules and processes to enter a cell, replicate and then spread to uninfected cells. Using lab-grown cells, Dr. Kalman and his colleagues identified specific cell proteins vaccinia uses to detach from an infected cell and move toward an uninfected cell. The proteins, members of the Abl-family (pronounced "able") of tyrosine kinases, are well known to cancer investigators because mutation of one family member, Abl, causes a rare form of cancer known as chronic myelogenous leukemia (CML). Gleevec inhibits Abl-family tyrosine kinases and has proved very useful in treating CML.

To learn whether Gleevec could prevent or lessen vaccinia's ability to spread in a living organism, the researchers treated mice with either saline solution or with Gleevec at a dose equivalent to that given to humans being treated for CML. Ne
'"/>

Source:NIH


Page: 1 2 3

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Jump-starting T Cells In Skin Cancer
3. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
4. Fox Chase Cancer Center scientists identify immune-system mutation
5. Breakthrough Microarray-based Technology for the Study of Cancer
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
8. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
9. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
10. New Breast Cancer Test Could Save Lives
11. Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cancer drug slows poxvirus mice

(Date:7/28/2014)... DUBLIN , July 28, 2014 ... the "Biometrics Market in Latin America 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biometrics measure and analyze biological ... facial patterns, irises, eye retinas, voice patterns, and hand ... one or more stored templates. The main purpose of ...
(Date:7/28/2014)... became the first man to reach the South Pole ... an international team of scientists led by Joe McConnell ... air pollution from industrial activities arrived long before. , ... spaced locations around the Antarctic continent, including the South ... reconstruction to date of lead pollution over the Earth,s ...
(Date:7/27/2014)... DURHAM, N.C. -- Microorganisms like bacteria and fungi can ... by antibiotics or antifungal drugs. These permanent mutations were ... strains to evolve. Now a new study has shown ... targets -- known as epimutations -- to gain the ... the new mechanism was discovered in a fungus called ...
Breaking Biology News(10 mins):Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3
... of evolution is periodically marked by explosions in biodiversity, ... of shapes and sizes. With a new analysis of ... have discovered that these diversifications proceeded head-first. By ... around the time of two separate extinction events, scientists ...
... are fascinating plant organs they not only anchor the ... Roots live in darkness and direct the activities of the ... Charles Darwin posited in The Power of Movement of Plants ... Due to the difficulty of accessing root tissue in ...
... Mediterranean diet with large amounts of vegetables and fish gives ... studies to be published by the Sahlgrenska Academy at the ... shown that a Mediterranean diet, based on a high consumption ... products such as meat and milk, leads to better health., ...
Cached Biology News:'Head-first' diversity shown to drive vertebrate evolution 2'Head-first' diversity shown to drive vertebrate evolution 3New tool offers unprecedented access for root studies 2
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
(Date:7/25/2014)... Albany, NY (PRWEB) July 26, 2014 ... Trials Review, H2, 2014" provides data on the ... This report provides elemental information and data relating ... Cerebral Stroke. , View full global Ischemic Stroke ... It includes an overview of the trial numbers ...
(Date:7/25/2014)... July 25, 2014 According to a ... Drugs Market - Global Industry Analysis, Size, Share, Growth, ... drugs market is estimated at USD 161,056.5 million in ... of 10.1% from 2014 to 2020, to reach an ... The biological drugs market is witnessing a significant growth ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- Xybion Corporation, the leading provider of ... in highly regulated industries, announced today that the ... Group Conference, Xybion International Exchange, on October 21-23, ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance Fusion.  ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... leaders, experts and foreign ministry delegations set to be involved in ... ... Singapore (PRWEB) March 2, 2009 -- Asia-Pacific,s largest and most ... Asia 2009 (GSA 2009), will be held in Singapore from 17th ...
... LOUIS, Feb. 27 A copy of the Company,s December ... Exchange Commission, may be obtained without charge at our website ... Sigma-Aldrich Corporation, P. O. Box 14508, St. Louis, Missouri 63178. ... Life Science and High Technology ...
... CV Therapeutics, Inc. (Nasdaq: CVTX ) today ... time in response to Astellas Pharma Inc.,s announcement that ... unsolicited tender offer for all outstanding common shares of ... in cash. CV Therapeutics, board of directors, in ...
Cached Biology Technology:News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 2News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 3CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 2CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 3
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
Purified anti-LAT...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Purified anti-human CD182 (CXCR2)...
Biology Products: